Information Provided By:
Fly News Breaks for November 5, 2019
BNTX
Nov 5, 2019 | 09:33 EDT
Wolfe Research analyst Akash Tewari initiated coverage of BioNTech with an Outperform rating and $21 price target. The analyst said early melanoma data and prior-generation PCV candidate compares favorably to competitor cancer vaccine programs.